School of Medicine


Showing 21-30 of 99 Results

  • Dylan Dodd

    Dylan Dodd

    Assistant Professor of Pathology and of Microbiology and Immunology

    Current Research and Scholarly InterestsHarnessing the gut microbiome to treat human disease.

  • Noelle Hanako Ebel

    Noelle Hanako Ebel

    Clinical Associate Professor, Pediatrics - Gastroenterology

    Current Research and Scholarly InterestsCurrent projects include:
    -indications for combined heart-liver transplantation
    -mitigating perioperative bleeding during cardiac surgery in children with Alagille syndrome
    -congenital heart disease and liver transplantation
    -subspecialty advocacy

  • Essam Ibraheem Elknawy

    Essam Ibraheem Elknawy

    Visiting Instructor, Pediatrics - Gastroenterology

    BioI am currently serving as a research fellow in pediatric gastroenterology department at Stanford University Medical Centre. I am an ECFMG Certified Physician. Over the past year, I have effectively immersed myself in the U.S. healthcare system. I am actively engaging in outpatient and inpatient services, as well as the operating room. Concurrently, I am involved in various IBD-related research projects. With six months of U.S. clinical experience (USCE) in pediatrics and three years of clinical practice in Egypt, I bring a well-rounded perspective. I graduated with honors from Mansoura University School of Medicine in 2020. My academic excellence is complemented by a robust track record in clinical research, evident through ongoing papers, posters, and oral presentations. My primary role centered on the execution of clinical research, with some laboratory work complementing it. I am currently the primary author for a study titled "Clinical Outcomes and Safety of Infliximab and Vedolizumab as Initial Biological Therapy in Pediatric Patients with Mild to Moderate IBD." Additionally, I contributed as the third author to another research project titled "Patient-Derived Organoids Illuminate a Mitochondrial Bioenergetic Inefficiency Associated with Decoupling in the Colon Epithelia of Pediatric Patients with Ulcerative Colitis." Proficiency in English, both spoken and written, is a point of pride for me. Beyond medicine, I find fulfilment in volunteering within underserved and disadvantaged communities. Athletics play a significant role in my life, and I am passionate about sports such as soccer, basketball, and fitness training. An Egyptian physician raised in the United Arab Emirates, I am dedicated to pursuing a career as a pediatric gastroenterologist in the United States.

  • Carlos O. Esquivel, M.D., Ph.D.,FACS

    Carlos O. Esquivel, M.D., Ph.D.,FACS

    Arnold and Barbara Silverman Professor in Pediatric Transplantation and Professor of Surgery (Abdominal Transplantation) and of Pediatrics (Gastroenterology, Hepatology and Nutrition)

    Current Research and Scholarly Interests1) Induction of immunotolerance
    2) Rejection of liver and intestinal transplantation.
    3) Clinical outcomes of children with unresectable liver tumors.

  • Nielsen Fernandez-Becker

    Nielsen Fernandez-Becker

    Clinical Associate Professor, Medicine - Gastroenterology & Hepatology

    BioI am the director of the Celiac Disease Program at Stanford and I am highly experienced in diagnosis and management of celiac disease and gluten associated disorders.
    My objective is to provide excellent and compassionate clinical care for my patients while seeking a better understanding of diseases I treat, particularly Celiac disease (CeD), eosinophilic esophagitis (EoE). My top priorities are patient care and translational research to make new discoveries and improve the care my patients.

  • Michael Fischbach

    Michael Fischbach

    Liu (Liao) Family Professor

    Current Research and Scholarly InterestsThe microbiome carries out extraordinary feats of biology: it produces hundreds of molecules, many of which impact host physiology; modulates immune function potently and specifically; self-organizes biogeographically; and exhibits profound stability in the face of perturbations. Our lab studies the mechanisms of microbiome-host interactions. Our approach is based on two technologies we recently developed: a complex (119-member) defined gut community that serves as an analytically manageable but biologically relevant system for experimentation, and new genetic systems for common species from the microbiome. Using these systems, we investigate mechanisms at the community level and the strain level.

    1) Community-level mechanisms. A typical gut microbiome consists of 200-250 bacterial species that span >6 orders of magnitude in relative abundance. As a system, these bacteria carry out extraordinary feats of metabolite consumption and production, elicit a variety of specific immune cell populations, self-organize geographically and metabolically, and exhibit profound resilience against a wide range of perturbations. Yet remarkably little is known about how the community functions as a system. We are exploring this by asking two broad questions: How do groups of organisms work together to influence immune function? What are the mechanisms that govern metabolism and ecology at the 100+ strain scale? Our goal is to learn rules that will enable us to design communities that solve specific therapeutic problems.

    2) Strain-level mechanisms. Even though gut and skin colonists live in communities, individual strains can have an extraordinary impact on host biology. We focus on two broad (and partially overlapping) categories:

    Immune modulation: Can we redirect colonist-specific T cells against an antigen of interest by expressing it on the surface of a bacterium? How do skin colonists induce high levels of Staphylococcus-specific antibodies in mice and humans?

    Abundant microbiome-derived molecules: By constructing single-strain/single-gene knockouts in a complex defined community, we will ask: What are the effects of bacterially produced molecules on host metabolism and immunology? Can the molecular output of low-abundance organisms impact host physiology?

    3) Cell and gene therapy. We have begun two new efforts in mammalian cell and gene therapies. First, we are developing methods that enable cell-type specific delivery of genome editing payloads in vivo. We are especially interested in delivery vehicles that are customizable and easy to manufacture. Second, we have begun a comprehensive genome mining effort with an emphasis on understudied or entirely novel enzyme systems with utility in mammalian genome editing.

  • Adam Frymoyer

    Adam Frymoyer

    Clinical Professor, Pediatrics - Neonatal and Developmental Medicine
    Clinical Associate Professor, Pediatrics

    Current Research and Scholarly InterestsMy research interests focus on understanding the clinical pharmacokinetics (PK) and pharmacodynamics (PD) of medicines used in complex pediatric populations. This includes identifying sources of variation in drug response through the application of population PK-PD modeling and simulation approaches. The goal is to ultimately apply this quantitative understanding to guide therapeutic decision-making in infants and children.